Skip to main content
Download PDF

Aspartoacylase promotes the process of tumour development and is associated with immune infiltrates in gastric cancer

BMC Cancer volume 23, Article number: 604 (2023) Cite this article

Abstract

Background

Aspartoacylase (ASPA) is a gene that plays an important role in the metabolic reprogramming of cancer. However, the clinical relevance of ASPA in gastric cancer (GC) has not been demonstrated.

Methods

The link between ASPA and the clinical features of GC was determined using two public genomic databases. The multivariate Cox proportional hazard model and generalised linear regression model were applied to examine whether the ASPA level is associated with the prognosis and other pathological factors. In addition, the role of specific genes in the infiltration of immune cells in the setting of GC was investigated using a further immunological database. The expression level of various proteins was detected using a western blotting assay. Transwell and methyl thiazolyl tetrazolium tests were applied for the detection of cellular invasion and proliferation, with small hairpin ribonucleic acid used to knockdown ASPA.

Results

According to the multivariate Cox regression results, the down-regulated ASPA expression is a distinct prognostic factor. Furthermore, ASPA has significant positive correlations with the infiltration of immune cells in GC lesions. Compared to the non-cancer tissues, the GC tissues had a significantly lower level of ASPA expression (p < 0.05). Using knockdown and overexpression techniques, it was demonstrated that ASPA affects the capacity of cell lines for GC to both proliferate and invade.

Conclusion

Overall, ASPA could promote the occurrence and development of GC and presents a promising predictive biomarker for the disease since it is favourably connected with immune infiltrates and negatively correlated with prognosis.

Peer Review reports

What is already known on this topic

The enzyme known as aspartoacylase (ASPA), which is found in the cytosol, catalyses the breakdown of n-acetylaspartate into aspartate and acetic acid, with the ASPA mutations leading to substantial increases in N-acetylaspartic acid concentrations in the brain, resulting in Canavan disease. The association between ASPA and cancer remains poorly understood.

What this study adds

This research discovered that tumour tissues have lower levels of ASPA expression. The knockdown and overexpression of ASPA was found to affect the proliferation and invasion ability of gastric cancer (GC). Overall, ASPA was confirmed to be adversely correlated with the prognosis of GC and positively correlated with the immune infiltration of the disease, and could present a useful indicator in clinical practice.

How this study might affect research, practice or policy

This research confirmed for the first time that ASPA may influence the development of GC and could be used as a predictor of the disease’s prognosis. It provides a new treatment idea for the potential future treatment of GC.

Introduction

Gastric cancer (GC) is currently the third leading cause of cancer-related death and one of the top five most common cancers in the world [1]. Genetic and environmental variables both impact GC, which is a complex and polygenic disease [2]. Important risk factors include inherited genetic factors, high-risk food intake, alcohol abuse, smoking and Helicobacter pylori infections [3]. Although there exist many treatments for GC, including surgery, chemotherapy, targeted therapy and immunotherapy, the prognosis remains poor [4, 5]. Gastric cancer is a highly aggressive type of cancer and its heterogeneous character significantly affects both its incidence and its course of development [6]. However, the basic mechanism behind the onset and progression of GC remains poorly understood. Therefore, exploring the genetic characteristics of GC in depth is a crucial strategy for better understanding the pathogenesis of the disease.

One of the main features of cancer is metabolic reprogramming, which also drives the change in tumour cells, potentially exhibiting a variety of biological traits. Aspartoacylase (ASPA), a cytosolic lipogenic enzyme, catalyses the transformation of N-acetylaspartic acid (NAA) into aspartate and acetate [7], which occurs particularly in the brain [8]. Canavan disease is induced by mutations in ASPA, which significantly increase the concentration of NAA in the brain [9, 10]. The correlation between ASPA and cancer remains largely unknown, with a lack of evidence demonstrating the key role of ASPA in the progression of prostate cancer and breast cancer [8, 11]. Furthermore, it is unclear whether ASPA affects the prognosis and clinicopathological status of GC. Therefore, in this study, clinical samples, cell lines and bioinformatic techniques are used for the validation of the prognostic performance of ASPA in GC and to identify molecular markers for future cancer treatments.

Materials and methods

Clinical samples

Five individuals who had their GC tumours surgically removed between January 2017 and December 2021 at the First Medical Centre of the Chinese PLA General Hospital provided the surgical specimens. Our local institutional review board (the Ethics Committee of the Chinese PLA General Hospital) gave its approval for the utilisation of the clinical samples (reference number: S2020-326-01). All patients were made aware of the trial and gave their informed consent.

Aspartoacylase data acquisition

The ASPA expression differences between tumour and control tissues were investigated using gene expression profiling interactive analysis (GEPIA) [12]. In addition, GEPIA was used for examining the role of ASPA in survival analysis. Various XENA (http://xena.ucsc.edu) datasets from The Cancer Genome Atlas (TCGA), including genomic data and clinical information, were obtained [13]. The Kaplan–Meier plot was utilised to verify the prognostic value of ASPA using the Gene Expression Omnibus (GEO) dataset [14].

Survival analysis of aspartoacylase

The association between ASPA expression and various prognosis and clinicopathologic variables was examined using multivariate Cox proportional regression. The patients with GC were equally split into two groups and their Kaplan–Meier curves were examined. The relationship between ASPA and the clinical variables was then examined using a general linear regression model.

Relationship between immunological infiltrates and aspartoacylase expression

The connection between ASPA and immunological infiltrates was examined using TIMER, an online tool for analysing immune infiltrates in TCGA samples (https://cistrome.shinyapps.io/timer/) [15]. Specific gene modules were used to examine the infiltration in tumour tissues, which included innate immune cells, antigen-processing cells and specific immune cells [16].

Analysis of gene set enrichment

To assess the significance of a candidate gene and the alterations between two biological states, a computer-based approach known as gene set enrichment analysis was used [17].

The nominal p-value and the normalised enrichment score were used to identify the enriched pathways in each phenotype [18]. If the false discovery rate of a gene set was < 0.05, the set was considered statistically significant.

Cell culture

The cell lines, HEK293T, AGS and BGC-823, were used in this investigation, with all the cell lines bought from the NCACC in China and kept at 37 °C in humidified incubators under a 5% carbon dioxide atmosphere. The Dulbecco’s modified Eagle medium–high-glucose medium used for all cell lines was supplemented with 10% fetal bovine serum (FBS) and 100 mg/mL of penicillin-streptomycin-glutamine (Gibco) [19].

Lentivirus production and infection

The plasmid containing small hairpin ASPA (shASPA) was constructed in pLKO vector and the small hairpin ribonucleic acid (shRNA) sequences were as follows: shASPA-1: AATCAGATAAACGTAGCAGGG and shASPA-2: ATGGGTTCCTCCAAAGATAGC. To produce lentiviruses, the appropriate customised Lenti-EF1-puro plasmids were co-transfected in the HEK293T cells in the ratio of 5:1:5 in mass with the psPAX2 vector (for packing, Addgene) and pCMV-VSV-G (for enveloping, Addgene) (ng). Fresh media was added following transfection for 24 h to create a virus-containing conditioned medium. After 72 h, the virus-containing medium was collected and, if required, concentrated. For lentiviral infection, 0.5–1 mL of the virus-containing medium or 0.1–0.5 mL of virus concentrate were added to the cell culture for 48 h. The culture was reset after 48 h and a specific selection of medication was introduced to determine the resistance [19].

Western blotting analysis

Passive lysis buffer (25 mM Tris-HCl, 150 mM NaCl, 0.5% CA630) containing a protease inhibitor cocktail was used to lyse the cells (Roche). The cells were boiled for five min in sodium dodecyl sulphate loading buffer before being lysed. Here, ASPA rabbit mAb (1: 1000; ab154503, Abcam) and GAPDH rabbit mAb (1: 1000; 10494-1-AP, Proteintech) were used as the main antibodies for the western blotting analysis, while all secondary antibodies (7074, Cell Signaling Technology) were employed at a 1:5000 dilution. A chemiluminescent substrate kit was purchased from Tanon, with Image J software used to quantify the findings [19].

Cell transwell assay

In the top chamber, 2000 AGS and BGC-823 cells were plated per well, while the bottom compartment was filled with complete media containing 20% FBS. Following this, cells that had entered the chamber were fixed for 10 min using 4% paraformaldehyde (Solarbio), with washing using PBS performed three times to clean the wells. Colonies were stained for 5 min using Solarbio’s Crystal Violet Regent. The number of cell masses was counted under a Nikon microscope [19].

10 Methyl thiazolyl tetrazolium assay

A total of 1,000 cells were seeded per well in triplicates on 96-well plates, with the cells then incubated for 1–10 days. The plate was incubated at 37 °C for a further 4 h after methyl thiazolyl tetrazolium (MTT; thiazolyl blue tetrazolium, Sigma) was added to each well at a final concentration of 0.5 mg/ml. Dimethyl sulfoxide was added to each well and 100 μL of the media was withdrawn after the incubation. The test-ready plate was then tested at OD490 using a Biotek Synergy H1 microplate reader. Growth curves were created using OD490 values broken down by days [19].

11 colony formation assay

A number of AGS and BGC-823 cells were seeded in six-well plates at 2,000 cells/well on the third day after infection and were then cultured for 14 days to form colonies. The cells were subsequently treated by washing with PBS, fixing in 4% paraformaldehyde for 15 min, staining with 0.5% crystal violet for 1 h and washing three times using ddH2O before they were photographed using a digital camera.

12 statistical analysis

The statistical analysis was conducted using R-3.6.0, with the R package [20] used to draw a survival curve. A p-value of 0.05 or less was used as the cut-off threshold. Image J’s Analyze→Gels→Plot Lanes function was used to evaluate the western blot test findings and to perform image quantification. The experimental data were expressed in terms of mean and standard deviation, with a two-tailed Student’s t-test used for the statistical analysis. For the MTT assay, the two-way analysis of variance method was used for the statistical analysis, with the experimental findings expressed in terms of mean and standard deviation (n = 3 repetitions).

Results

Downregulation of aspartoacylase expression in gastric cancer

The ASPA was downregulated in the GC cohort. As Fig. 1A shows, compared to similar nearby tissues, the cancer tissues had a lower expression level of ASPA. The western blots presented a similar expression pattern of ASPA in the tumour and non-tumour tissues (p < 0001) (Fig. 1B C).

Fig. 1
figure 1

 A. ASPA was downregulated in gastric cancer tissue. The num (T) and num (N) represent gastric cancer and similar nearby tissues, respectively. ASPA was decreased in tumor compared with paired samples. B, C. ASPA expression in clinical patient samples. D. The relationship between ASPA and overall survival. E. The relationship between ASPA and disease free survival. Error bar means ± SD, ***: p < 0.001

Full size image

Characterisation of the relationship between aspartoacylase and gastric cancer using bioinformatics analysis

We separated the samples into two equal groups according to the ASPA expression. The patients with low ASPA expression were more likely to survive than those with high ASPA expression (Fig. 1D).

The survival analysis also indicated that the disease-free survival time was significantly prolonged in the group with a lower level of ASPA compared to the patients who had a higher level of ASPA expression (Fig. 1E). The above results were obtained using the GEPIA database.

Furthermore, GEO GC data were used for verification. The overall survival was considerably longer for the patients with low ASPA expression than for those with high expression (Fig. 2).

Fig. 2
figure 2

Patients with low expressed ASPA had significantly longer overall survival

Full size image

In addition, the relationship between ASPA and specific clinicopathologic factors was explored. As shown in Fig. 3, the general linear regression model indicted that there is a strong correlation between ASPA expression and microsatellite instability.

Fig. 3
figure 3

 A. ASPA expression is significantly associated with microsatellite instability. B. Multivariate COX proportional hazard regression model showed ASPA was an independent prognosis biomarker

Full size image

According to the multivariate Cox proportional hazard regression model, the survival of the GC patients was significantly correlated with ASPA expression. In this research, the number of positive lymph nodes served as an independent prognostic predictor (Fig. 3). Given the above findings, ASPA expression may present a useful predictive biomarker. The implication is that a favourable outcome for GC is substantially related to a lower expression of ASPA.

Stimulation of the growth and invasion of gastric cancer by aspartoacylase

Both knockdown and overexpressing ASPA stable cell lines were constructed using lentiviruses (Fig. 4A). The results indicated that a stable cell line was successfully constructed. The MTT experiment results revealed that ASPA knockdown dramatically decreased the proliferative potential of the GC cell lines (p < 0.001) (Fig. 4B). Following overexpression, the ASPA improved the ability of the GC cell lines to proliferate (p < 0.01) (Fig. 4B). The transwell test findings demonstrated that the suppression of ASPA greatly reduced the capacity of the GC cell lines to invade, with increased GC cell line invasion observed following ASPA overexpression (Fig. 4C). The knockdown of the ASPA reduced the clonogenic ability of both the AGS and BGC-823 cells, while conversely, the overexpression of ASPA increased the clonogenic ability of both types of cells (Fig. 4D). The above findings suggest that ASPA could have an impact on the capacity of GC cells for invasion and proliferation.

Fig. 4
figure 4

 A. Knockdown and overexpression of ASPA using lenti-virus in AGS and BGC-823 cells. The knock-down and overexpression efficiency was determined by western blotting. B. MTT assay was used to detect the proliferation ability of AGS and BGC-823 cells. n = 3. Error bars mean ± SD, by two-way ANOVA analysis. C. Transwell assay was used to detect the invasion ability of AGS and BGC-823 cells. D. Colony formation assay was used to detect the proliferation ability of AGS and BGC-823 cells. ** :p < 0.01; *** :p < 0.001

Full size image

Aspartoacylase expression in relation to immune infiltration in gastric cancer

According to earlier study findings, tumour-infiltrating lymphocytes are regarded as an independent biomarker for predicting the prognosis of tumour patients who are the focus of immune therapy [21, 22]. As such, we aimed to confirm whether the ASPA expression in GC is connected to immune infiltration. There were significant correlations between the expression of ASPA and B cells (r = 0.206, p = 6.53e-05), CD8 + T cells (r = 0.354, p = 2.39e-12), CD4 + T cell (r = 0.46, p = 1.36e-20), macrophage (r = 0.562, p = 3.62e-32), neutrophil (r = 0.311, p = 9.00e-10) and dendritic cells (r = 0.452, p = 4.88e-20). In terms of GC, there was a negative correlation between ASPA levels and tumour purity (Fig. 5).

Fig. 5
figure 5

The expression of ASPA was significantly associated with B cell (r = 0.206, p = 6.53e-05), CD8 + T cell (r = 0.354, p = 2.39e-12), CD4 + T cell (r = 0.46, p = 1.36e-20), Macrophage (r = 0.562, p = 3.62e-32), Neutrophil (r = 0.311, p = 9.00e-10) and Dendritic cell (r = 0.452, p = 4.88e-20)

Full size image

Gene sets enriched in aspartoacylase expression phenotype

Based on the expression of ASPA as discussed above, all the samples used were again separated into two groups. Only the top enriched paths are presented in Fig. 6 due to space restrictions. As the figure shows, ASPA was preferentially enriched in the pathways associated with protein kinase B (AKT), cyclic adenosine 3’, 5’-monophosphate (cAMP), class-switch recombination (CSR), cyclin D1 and E2F transcription factor 1 (E2F1).

Fig. 6
figure 6

 A. GSEA analysis revealed ASPA was involved in many important pathways. B. Top 5 pathways were graphed

Full size image

Discussion

The growth and proliferation of cancer cells depend on metabolic reprogramming [23]. Evidence indicates that metabolic reprogramming may become a new direction for tumour-targeted therapy [24]. A number of studies have highlighted the benefits of using therapeutic targets of the tumour-associated metabolic pathways for anticancer medicines, and recently, important functions of amino acid metabolism in cancer development and prognosis have been found [25, 26]. Meanwhile, ASPA is an essential metabolite during the metabolic reprogramming of cancer. Therefore, in this investigation, we sought to ascertain whether ASPA plays a role in the development of GC. Here, it was discovered that the ASPA expression was markedly reduced in the GC tissues compared to nearby tissues. Sun et al. [11] reported that ASPA expression was decreased in both the breast and prostate cancer samples compared to the control samples. Long et al. reported that ASPA expression is also lower in glioma than in normal tissues [27], while Tsen et al. [28] demonstrated that efficient targeting of ASPA may diminish glioma development. As a result, we hypothesised that ASPA may behave as a tumour-promoting factor as GC evolves. Both the proliferation and the invasion capacity of GC cancer cell lines found to be altered in the ASPA knockdown and overexpression experiment. In this study, it was also demonstrated that ASPA is a prognostic factor. Poor survival was predicted by higher ASPA levels.

Contradictory findings pertaining to ASPA have been found in terms of different cancer types, with, for example, the hazard ratio (HR) of GC found to be > 1 and the HR of liver cancer found to be < 1, indicating that the role of ASPA in the development of malignant tumours may be organ-specific (Figure S1). Figure S1 also shows two cancer types with a HR of significantly higher than 1 (risk factor): stomach adenocarcinoma (STAD) and lung squamous cell carcinoma (LUSC).

Gastric cancer is a major health problem worldwide, ranking fifth among the most common malignancies and the third leading cause of cancer-related deaths worldwide [29]. There are four pathological types of GC: adenocarcinoma, adenosquamous carcinoma, squamous carcinoma and carcinoid carcinoma, with 95% of GCs gastric adenocarcinomas. Therefore, early diagnosis is crucial to the prognosis of patients with gastric adenocarcinoma (STAD). Higher levels of aromatic amino acids in gastric juice have been reported in the early stages of cancer progression [30]. This implies that there is an association between GC and amino acid metabolism. However, studies have reported the prevalence of H. pylori babA, homB, aspA and sabA genes in Turkey and their association with clinical outcomes [31]. It is known that H. pylori is one of the important factors in the development of GC, which appears to weaken the association between ASPA and STAD. Further discussion on the relationship between ASPA and STAD is required.

Meanwhile, LUSC is the most common type of non-small cell lung cancer, accounting for around 30% of lung cancer cases. Microarray data analysis of LUSC tumours identified four gene expression subtypes (canonical, basal, primitive and secretory) [32]. It has been reported that the gene characteristics of abnormal expression of amino acid and fatty acid metabolism are critically related to the pathogenesis of LUSC [33].

In addition, our results indicated that ASPA expression is significantly associated with microsatellite instability. Emerging data has suggested that microsatellite instability status is an effective biomarker for predicting the efficacy of immunotherapy for GC [34], with previous studies revealing its prognostic role [35]. Previous research has also shown that a variety of processes, including gene mutation encoding important enzymes engaged in metabolic pathways, may affect the metabolism of cancer cells. However, MSI-high (MSI-H) gastric and/or colorectal tumours are the only types to have mutations in ASPA (MSI-low or MSI-stable cancers do not), indicating that ASPA is related to tumour heterogeneity [36] and has a close connection with microsatellite instability.

In addition, in the present study, it was confirmed that ASPA is significantly related to immune infiltration in GC using the TIMER dataset. According to previous research, immune infiltration plays a significant role in patient outcomes, while tumour-associated macrophage and neutrophil infiltration play a significant role in patient prognosis and tumour chemosensitivity [37]. The immune microenvironment in MSI-H tumours of colorectal cancer samples present significant infiltration of lymphocytes [38].

Overall, ASPA is a useful biomarker that merits further study in relation to GC due to the finding that the expression of ASPA is correlated with several different immune markers in GC. This finding suggests that ASPA may be involved in controlling immune cell infiltration in this type of cancer.

Our results further indicated that ASPA is preferably enriched in cAMP, CSR, E2F1, AKT and cyclin D1-related pathways. These pathways are essential to the development of GC. In fact, cAMP plays an important role in cellular responses to many hormones and neurotransmitters [39]. One study found an interaction between histamine and cAMP in the human GC cell line, hgt-1 [40]. In the present study, while no association between the CSR signalling pathway and GC was found, the opposite was the case for E2F1. In a recent study, E2F1 was found to induce terminal differentiation-induced ncRNA (TINCR) transcriptional activity and accelerate GC progression through activation of the related signalling axis [41]. Regarding AKT, it has long been recognised that it is required for cell growth, proliferation and survival. Aberrant activation of AKT is one of the most common molecular findings in human malignancies, including GC, and is believed to play an important role in cancer cell survival and chemoresistance. Combining phosphatidylinositol 3-kinase/AKT pathway inhibitors with chemotherapy has been successful in reducing the chemoresistance in GC cell lines [42]. It has been proposed that the overexpression of cyclin D2 (but not cyclin D1) is closely associated with GC [43], while some have reported that cyclin D1 overexpression is, in fact, associated with the disease. The relationship between cyclin D2 and GC requires further discussion [44].

Several studies have confirmed that the expression of ASPA is decreased in tumours (prostate cancer, glioblastoma, neuroblastoma) [8, 45, 46] and is correlated with poor prognosis (glioblastoma, neuroblastoma). Current evidence suggests that ASPA is related to cell cycle regulation [47] and may subserve a signalling function [48]. Through the aforementioned routes, ASPA may potentially have an impact on the incidence and growth of malignancies. As a result, we may have better knowledge of how amino acid metabolism contributes to the development of cancer and its clinical significance to GC.

Conclusion

In conclusion, ASPA is associated with the occurrence and development of GC and affects the survival rate of patients with this disease. It was also observed that the expression of ASPA in GC is associated with immune infiltration. Our findings indicate a new possibility for the pathogenesis of GC, with ASPA potentially serving as an important regulatory factor and useful predictor of the immune infiltration of GC. Overall, the findings provide directions for further research and the treatment of GC. It is worth noting that altering amino acid metabolism remains an unexplored area in the current field of cancer research.

Data Availability

All data generated or analyzed during this study are included in this published article.

The data that support the findings of this study are available from the corresponding author, Baoqing Jia, upon reasonable request.

References

  1. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48. https://doi.org/10.1016/S0140-6736(20)31288-5.

    Article  CAS  PubMed  Google Scholar 

  2. Yusefi AR, Bagheri Lankarani K, Bastani P, Radinmanesh M, Kavosi Z. Risk factors for gastric Cancer: a systematic review. Asian Pac J Cancer Prev. 2018;19(3):591–603. https://doi.org/10.22034/APJCP.2018.19.3.591.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012. https://doi.org/10.3390/ijms21114012.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X.

    Article  CAS  PubMed  Google Scholar 

  5. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. https://doi.org/10.1016/S1470-2045(14)70420-6.

    Article  CAS  PubMed  Google Scholar 

  6. Gao JP, Xu W, Liu WT, Yan M, Zhu ZG. Tumor heterogeneity of gastric cancer: from the perspective of tumor-initiating cell. World J Gastroenterol. 2018;24(24):2567–81. https://doi.org/10.3748/wjg.v24.i24.2567.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Madhavarao CN, Arun P, Moffett JR, et al. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan’s disease. Proc Natl Acad Sci U S A. 2005;102(14):5221–6. https://doi.org/10.1073/pnas.0409184102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kheirkhah S, Javanzad M, Hoseinzadeh M, Hekmati Azar Mehrabani Z, Mohammadzadeh N, Monfaredan A. Monitoring prostate cancer (PCa) with appraise the gene expression of PRUNE2, NCAPD3 and ASPA and their connection with age, family history and tumor stage. Gene Rep. 2020;21. https://doi.org/10.1016/j.genrep.2020.100840.

  9. Jiang T, Guo J, Hu Z, Zhao M, Gu Z, Miao S. Identification of potential prostate Cancer-related Pseudogenes based on competitive endogenous RNA network hypothesis. Med Sci Monit. 2018;24:4213–39. https://doi.org/10.12659/MSM.910886.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Leone P, Shera D, McPhee SW, et al. Long-term follow-up after gene therapy for canavan disease. Sci Transl Med. 2012;4(165):165ra163. https://doi.org/10.1126/scitranslmed.3003454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sun C, Gu Y, Chen G, Du Y. Bioinformatics Analysis of Stromal Molecular Signatures Associated with breast and prostate Cancer. J Comput Biol. 2019;26(10):1130–9. https://doi.org/10.1089/cmb.2019.0045.

    Article  CAS  PubMed  Google Scholar 

  12. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. https://doi.org/10.1093/nar/gkx247.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–8. https://doi.org/10.1038/s41587-020-0546-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Szász AM, Lánczky A, Nagy Á, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322–33. https://doi.org/10.18632/oncotarget.10337.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Li T, Fan J, Wang B, et al. TIMER: a web server for Comprehensive Analysis of Tumor-Infiltrating Immune cells. Cancer Res. 2017;77(21):e108–10. https://doi.org/10.1158/0008-5472.CAN-17-0307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. https://doi.org/10.1186/s13059-016-1028-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007;23(23):3251–3. https://doi.org/10.1093/bioinformatics/btm369.

    Article  CAS  PubMed  Google Scholar 

  18. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50. https://doi.org/10.1073/pnas.0506580102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Zheng S, Lin J, Pang Z, et al. Aberrant cholesterol metabolism and Wnt/β-Catenin signaling Coalesce via Frizzled5 in supporting Cancer Growth. Adv Sci (Weinh). 2022;e2200750. https://doi.org/10.1002/advs.202200750.

  20. Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using ‘ggplot2’ 2019. Available from: https://CRAN.R-project.org/package=survminer [cited: 26th Jan 2022].

  21. Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30(21):2678–83. https://doi.org/10.1200/JCO.2011.37.8539.

    Article  PubMed  Google Scholar 

  22. Wong PF, Wei W, Smithy JW, et al. Multiplex quantitative analysis of Tumor-Infiltrating lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clin Cancer Res. 2019;25(8):2442–9. https://doi.org/10.1158/1078-0432.CCR-18-2652.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74–88. https://doi.org/10.1038/s41568-019-0216-7.

    Article  CAS  PubMed  Google Scholar 

  24. Muñoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012;3(1):e248. https://doi.org/10.1038/cddis.2011.123.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Koliarakis I, Psaroulaki A, Nikolouzakis TK, et al. Intestinal microbiota and colorectal cancer: a new aspect of research. J BUON. 2018;23(5):1216–34.

    PubMed  Google Scholar 

  26. Lacroix M, Riscal R, Arena G, Linares LK, Le Cam L. Metabolic functions of the tumor suppressor p53: implications in normal physiology, metabolic disorders, and cancer. Mol Metab. 2020;33:2–22. https://doi.org/10.1016/j.molmet.2019.10.002.

    Article  CAS  PubMed  Google Scholar 

  27. Long PM, Tighe SW, Driscoll HE, Fortner KA, Viapiano MS, Jaworski DM. Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest. J Cell Physiol. 2015;230(8):1929–43. https://doi.org/10.1002/jcp.24927.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Tsen AR, Long PM, Driscoll HE, et al. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. Int J Cancer. 2014;134(6):1300–10. https://doi.org/10.1002/ijc.28465.

    Article  CAS  PubMed  Google Scholar 

  29. Colquhoun A, Arnold M, Ferlay G, Kj, Forman D, Soerjomataram l. Global patterns of cardia and non-cardiagastric cancer incidence in 2012. Gut. 2015;64:1881–8. https://doi.org/10.1136/gutjnl-2014-308915.

    Article  CAS  PubMed  Google Scholar 

  30. Kai Deng S, Lin LZ, Li Y, Chen M, Wang Y. Yuwen Li.High.Levels of Aromatic Amino Acids in Gastric Juice duringthe Early Stages of Gastri Cance Progressio. PLoS One. 20122012;7(11):e49434. doi:https://doi.org/10.1371/journal.pone.0049434.

  31. Nimet Yilmaz and Meltem Koruk. Ozer the prevalence of Helicobacter Pylori babA, homB, aspA, and sabA genes and its relationship with clinical outcomes in Turkey. Can J Gastroenterol Hepatol. 2019;1271872. https://doi.org/10.1155/2019/1271872.

  32. Rana A, Alghamdi a, Maryam H. Al-Zahrani b. Integrated bioinformatics analyses identifying key transcriptomes correlated with prognosis and immune infiltrations in lung squamous cell carcinoma. Saudi J Biol Sci. 2023;30(4):103596. https://doi.org/10.1016/j.sjbs.2023.103596.

    Article  CAS  Google Scholar 

  33. Brooks KB, Givechian S, Ospanova. Aray Beisenbayeva, Katerina Politi 8 Rachel J.Perry. Multimodal analysis suggests differential mmune.metabolic crosstalk in lung squamous cell carcinomaand adenocarcinoma. 2022;6(1):8. doi: https://doi.org/10.1038/s41698-021-00248-2.

  34. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13. https://doi.org/10.1126/science.aan6733.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Polom K, Marano L, Marrelli D, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018;105(3):159–67. https://doi.org/10.1002/bjs.10663.

    Article  CAS  PubMed  Google Scholar 

  36. Oh HR, An CH, Yoo NJ, Lee SH. Somatic mutations of amino acid metabolism-related genes in gastric and colorectal cancers and their regional heterogeneity–a short report. Cell Oncol (Dordr). 2014;37(6):455–61. https://doi.org/10.1007/s13402-014-0209-1.

    Article  CAS  PubMed  Google Scholar 

  37. Waniczek D, Lorenc Z, Śnietura M, Wesecki M, Kopec A, Muc-Wierzgoń M. Tumor-Associated Macrophages and Regulatory T cells infiltration and the clinical outcome in Colorectal Cancer. Arch Immunol Ther Exp (Warsz). 2017;65(5):445–54. https://doi.org/10.1007/s00005-017-0463-9.

    Article  CAS  PubMed  Google Scholar 

  38. Kelderman S, Schumacher TN, Kvistborg P. Mismatch repair-deficient cancers are targets for Anti-PD-1 therapy. Cancer Cell. 2015;28(1):11–3. https://doi.org/10.1016/j.ccell.2015.06.012.

    Article  CAS  PubMed  Google Scholar 

  39. Paolo Sassone-Corsi. The cyclic AMP P athway. Cold Spring Harbor Laboratory Press. 2012;4(12):a011148. https://doi.org/10.1101/cshperspect.a011148.

    Article  CAS  Google Scholar 

  40. Shahin Emami C, Gespach M-E, Forgue-Lafitte Y, Broer, Gabriel Rosselin. Histamine and VIP interactions with receptor-cyclic AMP systems in the human gastric cancer cell line HGT-1. Life Sci. 1983;33(5):415–23. https://doi.org/10.1016/0024-3205(83)90789-0.

    Article  Google Scholar 

  41. Xu T-P, Wang Y-F, Xiong W-L, Ma P, Wang W-Y, Chen W-M, Huang M-D, Xia R, Wang R, Zhang E-B, Liu Y-W, De W. & Yong-Qian Shu. E2F1 induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR/STAU1/CDKN2B signaling axis. Cell Death & Disease 2017;8:e2837. doi:https://doi.org/10.1038/cddis.2017.205.

  42. Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric Cancer. Anticancer Res. 2011;31:4387–92.

    CAS  PubMed  Google Scholar 

  43. Yan–Shen Shan Hui–Ping Hsu Ming–Derg Lai Yu–Hsuan Hung Chih–Yang Wang Meng–Chi Yen Yi–Ling Chen. Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer. Oncology Letters. 2017;14(4): 4517–4526. doi: https://doi.org/10.3892/ol.2017.6736.

  44. Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol. 1999;189(2):194–200. https://doi.org/10.1002/(SICI)1096-9896(199910)189.

    Article  CAS  PubMed  Google Scholar 

  45. Long PM, Stradecki HM, Minturn JE, Wesley UV, Jaworski DM. Differential aminoacylase expression in neuroblastoma. Int J Cancer. 2011;129(6):1322–30. https://doi.org/10.1002/ijc.25798.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Panosyan EH, Lin HJ, Koster J, Lasky JL 3rd. In search of druggable targets for GBM amino acid metabolism. BMC Cancer. 2017;17(1):162. https://doi.org/10.1186/s12885-017-3148-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kumar S, Biancotti JC, Matalon R, de Vellis J. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease. J Neurosci Res. 2009;87(15):3415–27. https://doi.org/10.1002/jnr.22233.

    Article  CAS  PubMed  Google Scholar 

  48. Francis JS, Olariu A, McPhee SW, Leone P. Novel role for aspartoacylase in regulation of BDNF and timing of postnatal oligodendrogenesis. J Neurosci Res. 2006;84(1):151–69. https://doi.org/10.1002/jnr.20866.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of General Surgery, The First Medical Centre, Chinese PLA General Hospital, No. 28, Fuxing Road, Haidian District, Beijing, 100853, China

    Yalin Han, Maolin Xu, Zhipeng Teng, Peng Li, Peng Sun, Hongyi Liu & Baoqing Jia

  2. The Air Force Hospital of Northern Theater PLA, Shenyang, 110042, China

    Xuning Wang

  3. Department of Gastroenterology, The 305 Hospital of PLA, Beijing, 100017, China

    Rui Qin

  4. Air force medical center of PLA, Beijing, 100142, China

    Guodong Tan

  5. Department of Oncology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China

    Li Chen

  6. Department of Oncology, PLA Rocket Force Characteristic Medical Centre, Beijing, 100088, China

    Yalin Han

Authors
  1. Yalin Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuning Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maolin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhipeng Teng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rui Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guodong Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Peng Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hongyi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Li Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Baoqing Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Han YL conceived of the study. Wang XN and Xu ML participated in its design and collected the data. Teng ZP, Qin R, Tan GD, Li P and Sun P participate in the data analysis and statistics. Liu HY, Chen L and Jia BQ helped to draft the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Li Chen or Baoqing Jia.

Ethics declarations

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Chinese PLA General Hospital (reference number: S2020-326-01). All cell lines were purchased from ATCC (Shanghai, China). All patients were made aware of the trial and gave their informed consent.

Consent for publication

Not applicable.

Conflict of interest

The authors declare that they have no competing interests in this work.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Han, Y., Wang, X., Xu, M. et al. Aspartoacylase promotes the process of tumour development and is associated with immune infiltrates in gastric cancer. BMC Cancer 23, 604 (2023). https://doi.org/10.1186/s12885-023-11088-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-023-11088-7

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us